We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
-8.22%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
–
AUM
$385M
AUM Growth
-$22.8M
Cap. Flow
+$26.4M
Cap. Flow %
6.85%
Top 10 Hldgs %
77.48%
Holding
22
New
4
Increased
4
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$19.7M
2
AKRO
Akero Therapeutics
AKRO
+$9.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$8.88M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.07M
5
DXCM icon
DexCom
DXCM
+$6.72M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$10M
2
NTRA icon
Natera
NTRA
+$9.64M
3
UTHR icon
United Therapeutics
UTHR
+$7.69M
4
INSM icon
Insmed
INSM
+$5.39M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.2B
$44.4M 11.53%
74,990
– –
NTRA icon
2
Natera
NTRA
$46.4B
$39.6M 10.27%
279,764
-60,000
-18% -$9.64M
ICLR icon
3
Icon
ICLR
$12.9B
$36.6M 9.51%
209,190
– –
INSM icon
4
Insmed
INSM
$29.5B
$33.8M 8.78%
443,300
-70,400
-14% -$5.39M
ILMN icon
5
Illumina
ILMN
$29B
$27.2M 7.07%
343,361
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$13.3B
$27M 7.02%
382,612
-36,600
-9% -$2.46M
NBIX icon
7
Neurocrine Biosciences
NBIX
$16.7B
$24.9M 6.46%
225,100
+70,100
+45% +$8.88M
DXCM icon
8
DexCom
DXCM
$33.2B
$24.4M 6.33%
356,921
+82,370
+30% +$6.72M
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.65B
$22.7M 5.9%
627,600
– –
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$29B
$17.7M 4.6%
65,656
-10,600
-14% -$2.72M
PRCT icon
11
Procept Biorobotics
PRCT
$1.26B
$17.4M 4.52%
299,089
+66,000
+28% +$4.51M
EXAS
12
DELISTED
Exact Sciences
EXAS
$16.8M 4.37%
+388,650
New +$19.7M
INSP icon
13
Inspire Medical Systems
INSP
$1.73B
$12.9M 3.36%
81,121
-55,482
-41% -$10M
AGIO icon
14
Agios Pharmaceuticals
AGIO
$1.94B
$9.69M 2.52%
330,830
– –
AKRO
15
DELISTED
Akero Therapeutics
AKRO
$9.16M 2.38%
+226,400
New +$9.6M
ASND icon
16
Ascendis Pharma A/S
ASND
$16.5B
$8.81M 2.29%
+56,500
New +$8.07M
TMDX icon
17
Transmedics
TMDX
$3.05B
$6.77M 1.76%
100,661
+82,600
+457% +$5.68M
ISRG icon
18
Intuitive Surgical
ISRG
$138B
$2.17M 0.56%
4,390
– –
VIR icon
19
Vir Biotechnology
VIR
$1.5B
$1.56M 0.4%
+240,500
New +$2.14M
IMCR icon
20
Immunocore
IMCR
$1.73B
$1.37M 0.36%
46,300
– –
UTHR icon
21
United Therapeutics
UTHR
$22.7B
– –
-21,802
Closed -$7.69M
GRAL
22
GRAIL Inc
GRAL
$3.29B
– –
-53,124
Closed -$948K

Similar funds

PIFP
Partners in Financial Planning Salem, Virginia $603M AUM 12.72% 1-Year Est. Return
IECM
Intrinsic Edge Capital Management Chicago, Illinois $603M AUM 66.97% 1-Year Est. Return
ERWM
Elk River Wealth Management Denver, Colorado $602M AUM 22.77% 1-Year Est. Return
CIG
Capricorn Investment Group Palo Alto, California $602M AUM 165.22% 1-Year Est. Return
JHCP
Jackson Hole Capital Partners Tulsa, Oklahoma $605M AUM 22.77% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
OCAM
Onex Canada Asset Management Toronto, Ontario, Canada $601M AUM 15.16% 1-Year Est. Return

Eagle Health Investments's Q1 2025 Portfolio in Review

As of Q1 2025, Eagle Health Investments held 22 positions worth $385M, down 5.6% from $408M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Eagle Health Investments deployed $26.4M of net new capital in Q1 2025, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Exact Sciences: 388,650 shares worth $16.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Inspire Medical Systems, an estimated $10M trimmed.

  • Eagle Health Investments's largest Q1 2025 buy was Exact Sciences: 388,650 shares worth $16.8M.
  • Eagle Health Investments added most to Neurocrine Biosciences in Q1 2025, an estimated $8.88M increase.
  • Eagle Health Investments's biggest Q1 2025 reduction was Inspire Medical Systems, cutting an estimated $10M.
  • Eagle Health Investments fully exited United Therapeutics in Q1 2025, selling an estimated $7.69M.
  • Eagle Health Investments's ten largest holdings make up 77% of its $385M portfolio in Q1 2025.
  • Eagle Health Investments opened 4 new positions and closed 2 in Q1 2025.
  • Eagle Health Investments's portfolio value fell 5.6% quarter-over-quarter to $385M.

Based on Eagle Health Investments's 13F filing for Q1 2025, filed 12 May 2025.